PATTERNS OF RESCUE MEDICATION USAGE IN ASTHMA PATIENTS RECORDED BY THE ELECTRONIC PROAIR DIGIHALER

SESSION TITLE: Getting It Right: Personalized Strategies for Better Asthma Control SESSION TYPE: Original Investigations PRESENTED ON: 10/20/2019 2:15 PM - 3:15 PM PURPOSE: Simple and objective tools to identify patients with poor asthma control are still required. Approved by the Food and Drug Administration in Dec-2018, ProAir Digihaler, the first commercially available inhaler with an integrated electronic module, delivers 90 mcg albuterol per dose, detects the date and time when a dose was prepared and records the inhalation profile. This analysis describes the pattern of albuterol use recorded by Digihaler in exacerbation-prone asthma patients. METHODS: Eligible patients (≥18yrs) had ≥1 severe clinical asthma exacerbations (CAEs) over the previous 12 months, were on moderate-dose ICS (± LABA) and stable doses of asthma controller for at least 3 months. During a 12-week, open-label study, the electronic component of Digihaler recorded each inhaler use. Data were downloaded at the end of the study, and analyzed together with data on CAEs. Episodes of use were defined as consecutive inhalations within 60 seconds. RESULTS: 360 of 381 patients (94.5%) made ≥1 valid inhalation; 64 experienced 78 CAEs. 60.8% episodes of use comprised a single inhalation, 35.9% 2 inhalations, 3.3% ≥3 inhalations. On average, patients without CAEs used ProAir Digihaler 1.17 (SD=1.51) times per day vs. 1.82 (2.13) for those who had ≥1 CAE (outside the exacerbation period). During a CAE (± 14 days from symptom onset) patients used ProAir Digihaler, on average, 2.63 (3.77) times per day. CONCLUSIONS: The usage patterns reported in this study suggests even patients without exacerbations have a high burden of rescue inhaler use and would require additional therapy based on asthma guidelines. CLINICAL IMPLICATIONS: ProAir Digihaler provides a picture of patients’ patterns of inhaled rescue medication usage, and offers an opportunity for healthcare providers to identify patients with poor asthma control and possibly an impending exacerbation. DISCLOSURES: Employee relationship with Teva Pharmaceuticals Please note: >$100000 Added 03/14/2019 by Michael De Pietro, source=Web Response, value=Salary No relevant relationships by Lena Granovsky, source=Web Response No relevant relationships by Yonathan Hadar, source=Web Response Employee relationship with Teva Pharmaceuticals Please note: >$100000 Added 03/15/2019 by Tanisha Hill, source=Web Response, value=Salary No relevant relationships by Henry hrystyn, source=Web Response No relevant relationships by Or Itzahary, source=Web Response Employee relationship with TEVA pharmaceuticals Please note: >$100000 Added 03/15/2019 by Thomas Li, source=Web Response, value=Salary Scientific Medical Advisor relationship with Teva Please note: $1001 - $5000 Added 03/12/2019 by Roy Pleasants, source=Web Response, value=Consulting fee Consultant relationship with Boehringer Ingelheim Please note: $5001 - $20000 Added 03/12/2019 by Roy Pleasants, source=Web Response, value=Honoraria No relevant relationships by Michael Reich, source=Web Response Employee relationship with Teva Pharmaceuticals Please note: >$100000 Added 06/24/2019 by Guilherme Safioti, source=Web Response, value=Salary